Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 42 |
| List of Tables | 37 | 6 |
| List of Figures | 43 | 1 |
| Introduction | 44 | 1 |
| Global Markets Direct Report Coverage | 44 | 1 |
| Multiple Sclerosis Overview | 45 | 1 |
| Therapeutics Development | 46 | 2 |
| Pipeline Products for Multiple Sclerosis Overview | 46 | 1 |
| Pipeline Products for Multiple Sclerosis Comparative Analysis | 47 | 1 |
| Multiple Sclerosis Therapeutics under Development by Companies | 48 | 16 |
| Multiple Sclerosis Therapeutics under Investigation by Universities/Institutes | 64 | 2 |
| Multiple Sclerosis Pipeline Products Glance | 66 | 4 |
| Late Stage Products | 66 | 1 |
| Clinical Stage Products | 67 | 1 |
| Early Stage Products | 68 | 1 |
| Unknown Stage Products | 69 | 1 |
| Multiple Sclerosis Products under Development by Companies | 70 | 20 |
| Multiple Sclerosis Products under Investigation by Universities/Institutes | 90 | 3 |
| Multiple Sclerosis Companies Involved in Therapeutics Development | 93 | 178 |
| 4D Pharma Plc | 93 | 1 |
| 4SC AG | 94 | 1 |
| AB Science SA | 95 | 1 |
| AbbVie Inc. | 96 | 1 |
| Ablynx NV | 97 | 1 |
| Acorda Therapeutics, Inc. | 98 | 1 |
| Actelion Ltd | 99 | 1 |
| Addex Therapeutics Ltd | 100 | 1 |
| Adhaere Pharmaceuticals, Inc. | 101 | 1 |
| Aegis Therapeutics, LLC | 102 | 1 |
| Affectis Pharmaceuticals AG | 103 | 1 |
| AiCuris GmbH &Co. KG | 104 | 1 |
| Alkermes Plc | 105 | 1 |
| Alpha Cancer Technologies Inc. | 106 | 1 |
| Amarna Therapeutics B.V. | 107 | 1 |
| Anavex Life Sciences Corp. | 108 | 1 |
| Antisense Therapeutics Limited | 109 | 1 |
| Antitope Limited | 110 | 1 |
| Aphios Corporation | 111 | 1 |
| Apitope International NV | 112 | 1 |
| Arena Pharmaceuticals, Inc. | 113 | 1 |
| Argos Therapeutics, Inc. | 114 | 1 |
| Arrien Pharmaceuticals, LLC | 115 | 1 |
| Artielle ImmunoTherapeutics, Inc. | 116 | 1 |
| Astellas Pharma Inc. | 117 | 1 |
| Asterias Biotherapeutics, Inc. | 118 | 1 |
| Atara Biotherapeutics, Inc. | 119 | 1 |
| Athersys, Inc. | 120 | 1 |
| Axxam SpA | 121 | 1 |
| Baliopharm AG | 122 | 1 |
| Bio-Cancer Treatment International Limited | 123 | 1 |
| BioAegis Therapeutics, Inc. | 124 | 1 |
| BIOCAD | 125 | 1 |
| Biocon Limited | 126 | 1 |
| Biogen, Inc. | 127 | 1 |
| Biogenomics Limited | 128 | 1 |
| Biokine Therapeutics Ltd. | 129 | 1 |
| Biomar Microbial Technologies | 130 | 1 |
| Bionature E.A. Ltd. | 131 | 1 |
| Bioncotech Therapeutics S.L. | 132 | 1 |
| Bionovis SA | 133 | 1 |
| Bionure Farma, S.L. | 134 | 1 |
| Biovista Inc. | 135 | 1 |
| Bird Rock Bio, Inc. | 136 | 1 |
| Bolder Biotechnology, Inc. | 137 | 1 |
| BrainStorm Cell Therapeutics Inc. | 138 | 1 |
| C4X Discovery Holdings PLC | 139 | 1 |
| Caladrius Biosciences, Inc. | 140 | 1 |
| CASI Pharmaceuticals Inc. | 141 | 1 |
| Catalyst Pharmaceuticals, Inc. | 142 | 1 |
| Celgene Corporation | 143 | 1 |
| Cell Cure Neurosciences, Ltd. | 144 | 1 |
| Cell2B S.A. | 145 | 1 |
| Cellceutix Corporation | 146 | 1 |
| Chong Kun Dang Pharmaceutical Corp. | 147 | 1 |
| Cognosci, Inc. | 148 | 1 |
| Coherus BioSciences, Inc. | 149 | 1 |
| Commence Bio, Inc. | 150 | 1 |
| Compugen Ltd. | 151 | 1 |
| Connexios Life Sciences Pvt. Ltd. | 152 | 1 |
| Critical Outcome Technologies Inc. | 153 | 1 |
| CuraVac, Inc. | 154 | 1 |
| Cyxone AB | 155 | 1 |
| Dimerix Bioscience Pty Ltd | 156 | 1 |
| Eisai Co., Ltd. | 157 | 1 |
| Endece, LLC | 158 | 1 |
| Euroscreen S.A. | 159 | 1 |
| Evgen Pharma Plc | 160 | 1 |
| Evotec AG | 161 | 1 |
| F. Hoffmann-La Roche Ltd. | 162 | 1 |
| Flex Pharma, Inc. | 163 | 1 |
| Forward Pharma A/S | 164 | 1 |
| FPRT Bio Inc. | 165 | 1 |
| Gemac | 166 | 1 |
| Genervon Biopharmaceuticals, LLC | 167 | 1 |
| GeNeuro SA | 168 | 1 |
| Genzyme Corporation | 169 | 1 |
| GlaxoSmithKline Plc | 170 | 1 |
| Glialogix, Inc. | 171 | 1 |
| Hansa Medical AB | 172 | 1 |
| Hanwha Chemical Corporation | 173 | 1 |
| Harbor Therapeutics, Inc. | 174 | 1 |
| HitGen LTD | 175 | 1 |
| Hutchison MediPharma Limited | 176 | 1 |
| Iltoo Pharma | 177 | 1 |
| Immune Response BioPharma, Inc. | 178 | 1 |
| ImmuNext, Inc. | 179 | 1 |
| Immungenetics AG | 180 | 1 |
| InDex Pharmaceuticals AB | 181 | 1 |
| Innate Immunotherapeutics Ltd | 182 | 1 |
| Inovio Pharmaceuticals, Inc. | 183 | 1 |
| Io Therapeutics, Inc. | 184 | 1 |
| Jyant Technologies, Inc. | 185 | 1 |
| Kadimastem Ltd. | 186 | 1 |
| Kadmon Corporation, LLC | 187 | 1 |
| KAHR medical Ltd. | 188 | 1 |
| KaloBios Pharmaceuticals, Inc. | 189 | 1 |
| Kareus Therapeutics, SA | 190 | 1 |
| Karo Pharma AB | 191 | 1 |
| Karyopharm Therapeutics, Inc. | 192 | 1 |
| Kezar Life Sciences, Inc. | 193 | 1 |
| Kineta, Inc. | 194 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 195 | 1 |
| Lead Discovery Center GmbH | 196 | 1 |
| LFB S.A. | 197 | 1 |
| Lipocure Ltd. | 198 | 1 |
| MacroGenics, Inc. | 199 | 1 |
| MAKScientific, LLC | 200 | 1 |
| Mallinckrodt Plc | 201 | 1 |
| Mapi Pharma Ltd. | 202 | 1 |
| Marathon Pharmaceuticals, LLC | 203 | 1 |
| MedAnnex Ltd | 204 | 1 |
| MedDay SA | 205 | 1 |
| Medestea Research &Production S.p.A. | 206 | 1 |
| MedImmune, LLC | 207 | 1 |
| Meiji Seika Pharma Co., Ltd. | 208 | 1 |
| Merck KGaA | 209 | 1 |
| Meta-IQ ApS | 210 | 1 |
| Mitochon Pharmaceuticals, Inc. | 211 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 212 | 1 |
| MorphoSys AG | 213 | 1 |
| Neuralstem, Inc. | 214 | 1 |
| Neuren Pharmaceuticals Limited | 215 | 1 |
| Neurotec Pharma SL | 216 | 1 |
| New World Laboratories, Inc. | 217 | 1 |
| Novartis AG | 218 | 1 |
| NovImmune SA | 219 | 1 |
| Nuevolution AB | 220 | 1 |
| Octapharma AG | 221 | 1 |
| Omeros Corporation | 222 | 1 |
| OncoImmune, Inc. | 223 | 1 |
| Opexa Therapeutics, Inc. | 224 | 1 |
| OPKO Health, Inc. | 225 | 1 |
| OSE Immunotherapeutics | 226 | 1 |
| Parvus Therapeutics, Inc. | 227 | 1 |
| Peptinov SAS | 228 | 1 |
| Pfenex Inc. | 229 | 1 |
| Pfizer Inc. | 230 | 1 |
| PharmaEssentia Corporation | 231 | 1 |
| PharmatrophiX, Inc. | 232 | 1 |
| Pharmaxis Limited | 233 | 1 |
| Pieris Pharmaceuticals, Inc. | 234 | 1 |
| Plexxikon Inc. | 235 | 1 |
| ProNoxis AB | 236 | 1 |
| Prothena Corporation Plc | 237 | 1 |
| Q Therapeutics, Inc. | 238 | 1 |
| ReceptoPharm, Inc. | 239 | 1 |
| RedHill Biopharma Ltd. | 240 | 1 |
| RegeneRx Biopharmaceuticals, Inc. | 241 | 1 |
| Regenesance BV | 242 | 1 |
| Resverlogix Corp. | 243 | 1 |
| ReveraGen BioPharma, Inc. | 244 | 1 |
| Rigel Pharmaceuticals, Inc. | 245 | 1 |
| SanBio, Inc. | 246 | 1 |
| Santhera Pharmaceuticals Holding AG | 247 | 1 |
| Sareum Holdings Plc | 248 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 249 | 1 |
| Sorrento Therapeutics, Inc. | 250 | 1 |
| Symic Biomedical, Inc. | 251 | 1 |
| Synthon Holdings BV | 252 | 1 |
| Targazyme, Inc. | 253 | 1 |
| Teikoku Pharma USA, Inc. | 254 | 1 |
| Teva Pharmaceutical Industries Ltd. | 255 | 1 |
| Therapix Biosciences Ltd | 256 | 1 |
| TikoMed AB | 257 | 1 |
| Toleranzia AB | 258 | 1 |
| Topas Therapeutics GmbH | 259 | 1 |
| TxCell SA | 260 | 1 |
| Vaccinex, Inc. | 261 | 1 |
| Vakzine Projekt Management GmbH | 262 | 1 |
| Vertex Pharmaceuticals Incorporated | 263 | 1 |
| Virogenomics BioDevelopment, Inc. | 264 | 1 |
| Vitae Pharmaceuticals, Inc. | 265 | 1 |
| VivaCell Biotechnology Espana S.L. | 266 | 1 |
| Xenetic Biosciences (UK) Limited | 267 | 1 |
| XL-protein GmbH | 268 | 1 |
| Yungjin Pharm. Co., Ltd. | 269 | 1 |
| Zydus Cadila Healthcare Limited | 270 | 1 |
| Multiple Sclerosis Therapeutics Assessment | 271 | 53 |
| Assessment by Monotherapy Products | 271 | 1 |
| Assessment by Combination Products | 272 | 1 |
| Assessment by Target | 273 | 29 |
| Assessment by Mechanism of Action | 302 | 18 |
| Assessment by Route of Administration | 320 | 2 |
| Assessment by Molecule Type | 322 | 2 |
| Drug Profiles | 324 | 580 |
| (buspirone + carbidopa + levodopa) Drug Profile | 324 | 1 |
| (clarithromycin + clofazimine + rifabutin) Drug Profile | 325 | 7 |
| 2ME2 Drug Profile | 332 | 3 |
| AB-002 Drug Profile | 335 | 1 |
| ABS-11 Drug Profile | 336 | 1 |
| ABT-555 Drug Profile | 337 | 1 |
| ACT-101 Drug Profile | 338 | 2 |
| ADX-88178 Drug Profile | 340 | 2 |
| AFC-5128 Drug Profile | 342 | 1 |
| AGS-010 Drug Profile | 343 | 2 |
| AIC-284 Drug Profile | 345 | 1 |
| AKP-11 Drug Profile | 346 | 2 |
| aldesleukin Drug Profile | 348 | 1 |
| ALKS-8700 Drug Profile | 349 | 2 |
| amiselimod hydrochloride Drug Profile | 351 | 2 |
| Anatabine Drug Profile | 353 | 3 |
| ANAVEX-273 Drug Profile | 356 | 8 |
| Annexuzlimab Drug Profile | 364 | 1 |
| ANT-1034 Drug Profile | 365 | 1 |
| APD-334 Drug Profile | 366 | 2 |
| APH-1305 Drug Profile | 368 | 1 |
| APH-1403 Drug Profile | 369 | 1 |
| ARN-6039 Drug Profile | 370 | 1 |
| ASTOPC-1 Drug Profile | 371 | 5 |
| ATL-1102 Drug Profile | 376 | 5 |
| ATXMS-2 Drug Profile | 381 | 1 |
| ATXMS-3 Drug Profile | 382 | 1 |
| AX-007 Drug Profile | 383 | 1 |
| AX-024 Drug Profile | 384 | 1 |
| AZD-8797 Drug Profile | 385 | 1 |
| BA-024 Drug Profile | 386 | 1 |
| BBT-032 Drug Profile | 387 | 1 |
| BCT-200 Drug Profile | 388 | 1 |
| BIIB-061 Drug Profile | 389 | 1 |
| biotin Drug Profile | 390 | 4 |
| BKT-130 Drug Profile | 394 | 1 |
| BN-201 Drug Profile | 395 | 2 |
| BNV-004 Drug Profile | 397 | 1 |
| BNZ-1321 Drug Profile | 398 | 1 |
| BVA-101 Drug Profile | 399 | 1 |
| CAR-208 Drug Profile | 400 | 1 |
| CBP-307 Drug Profile | 401 | 1 |
| CD-24Fc Drug Profile | 402 | 2 |
| Cellular Immunotherapy for Central Nervous System Disorders Drug Profile | 404 | 1 |
| Cellular Immunotherapy for Multiple Sclerosis Drug Profile | 405 | 1 |